We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Laboratory Accuracy in Neonatal Bilirubin The Search for Truth in Laboratory Medicine

Stanley F. Lo, PhD1,2
[+] Author Affiliations
1Department of Pathology, Medical College of Wisconsin, Milwaukee
2Department of Pathology and Laboratory Medicine, Children’s Hospital of Wisconsin, Milwaukee
JAMA Pediatr. 2016;170(6):529-530. doi:10.1001/jamapediatrics.2016.0279.
Text Size: A A A
Published online


In this issue of JAMA Pediatrics, Kuzniewicz et al1 describe the consequences of an in vitro diagnostics manufacturer altering the values assigned to their calibrators for the determination of neonatal bilirubin concentrations. Notable in the study are the sizes of the prerecalibration population (n = 61 945) and postrecalibration group (n = 47 359). This significantly large number of newborn samples was evaluated for exceeding the American Academy of Pediatrics phototherapy threshold and the effect on phototherapy of newborns during their birth hospitalization and its effect on readmission for phototherapy. The postrecalibration resulted in patient bilirubin levels decreasing by 1.18 mg/dL (to convert to micromoles per liter, multiply by 17.1) and consequently decreasing the number of infants above the American Academy of Pediatrics phototherapy threshold. Changes to bilirubin assays are not limited to reassigning values to calibrators. Changes to different manufactured lots of reagents is very common, while changing to an alternate bilirubin assay is uncommon.2 Even instrumentation changes may result in new bilirubin assays that may occur more frequently owing to the consolidation of health systems and the need for clinical laboratories to standardize their instrumentation.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Bilirubin, an assay more precise than the interpretation
Posted on April 23, 2016
Kenneth Harkavy
Reston Hospital Center
Conflict of Interest: None Declared
A precision on the order of a few percent is more than in the past, so I for one am grateful. Is a new assay that \"underestimates\" the serum bilirubin by 1.18mg% of concern? Should it require a change in the position of the treatment curves, whether published by the AAP or the NICE (National Institute for Health and Care and Excellence https://www.nice.org.uk/)? There are precious little data from randomized trials about safe levels of bilirubin. What is agreed upon is based on population data, case studies and personal opinion. Exchange levels are usually 5mg% above phototherapy levels, providing the first margin of safety. Exchange levels are typically below levels associated with encephalopathy, providing another safety margin. In fact, in my experience referral NICU's rarely if ever perform an exchange, even when levels exceed guidelines.

I conclude that the new lower values are a blessing: fewer infants treated.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference